Literature DB >> 26231116

Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.

Gail D Sckisel1, Myriam N Bouchlaka1, Arta M Monjazeb2, Marka Crittenden3, Brendan D Curti3, Danice E C Wilkins4, Kory A Alderson4, Can M Sungur1, Erik Ames1, Annie Mirsoian1, Abhinav Reddy1, Warren Alexander5, Athena Soulika6, Bruce R Blazar7, Dan L Longo8, Robert H Wiltrout9, William J Murphy10.   

Abstract

Primary T cell activation involves the integration of three distinct signals delivered in sequence: (1) antigen recognition, (2) costimulation, and (3) cytokine-mediated differentiation and expansion. Strong immunostimulatory events such as immunotherapy or infection induce profound cytokine release causing "bystander" T cell activation, thereby increasing the potential for autoreactivity and need for control. We show that during strong stimulation, a profound suppression of primary CD4(+) T-cell-mediated immune responses ensued and was observed across preclinical models and patients undergoing high-dose interleukin-2 (IL-2) therapy. This suppression targeted naive CD4(+) but not CD8(+) T cells and was mediated through transient suppressor of cytokine signaling-3 (SOCS3) inhibition of the STAT5b transcription factor signaling pathway. These events resulted in complete paralysis of primary CD4(+) T cell activation, affecting memory generation and induction of autoimmunity as well as impaired viral clearance. These data highlight the critical regulation of naive CD4(+) T cells during inflammatory conditions.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26231116      PMCID: PMC4770886          DOI: 10.1016/j.immuni.2015.06.023

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  37 in total

Review 1.  Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?

Authors:  Julia K Tietze; Gail D Sckisel; Hui-Hua Hsiao; William J Murphy
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

Review 2.  Revisiting immune exhaustion during HIV infection.

Authors:  Alka Khaitan; Derya Unutmaz
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

3.  Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients.

Authors:  Meenakshi Sachdeva; Margaret A Fischl; Rajendra Pahwa; Naresh Sachdeva; Savita Pahwa
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.

Authors:  Vanessa Berner; Haiyan Liu; Qing Zhou; Kory L Alderson; Kai Sun; Jonathan M Weiss; Timothy C Back; Dan L Longo; Bruce R Blazar; Robert H Wiltrout; Lisbeth A Welniak; Doug Redelman; William J Murphy
Journal:  Nat Med       Date:  2007-03-04       Impact factor: 53.440

5.  Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

Authors:  Julia K Tietze; Danice E C Wilkins; Gail D Sckisel; Myriam N Bouchlaka; Kory L Alderson; Jonathan M Weiss; Erik Ames; Kevin W Bruhn; Noah Craft; Robert H Wiltrout; Dan L Longo; Lewis L Lanier; Bruce R Blazar; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

6.  Interleukin-2 inhibits polarization to T helper type 1 cells and prevents mouse acute graft-versus-host disease through up-regulating suppressors of cytokine signalling-3 expression of naive CD4+ T cells.

Authors:  J Zhao; T Zhang; H He; Y Xie
Journal:  Clin Exp Immunol       Date:  2010-02-02       Impact factor: 4.330

7.  Sustained signaling by canonical helper T cell cytokines throughout the reactive lymph node.

Authors:  Georgia Perona-Wright; Katja Mohrs; Markus Mohrs
Journal:  Nat Immunol       Date:  2010-04-25       Impact factor: 25.606

Review 8.  Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Authors:  Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2009-10-30       Impact factor: 16.687

9.  Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.

Authors:  Arta M Monjazeb; Julia K Tietze; Steven K Grossenbacher; Hui-Hua Hsiao; Anthony E Zamora; Annie Mirsoian; Brent Koehn; Bruce R Blazar; Jonathan M Weiss; Robert H Wiltrout; Gail D Sckisel; William J Murphy
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

10.  Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Authors:  Begoña Comin-Anduix; Yohan Lee; Jason Jalil; Alain Algazi; Pilar de la Rocha; Luis H Camacho; Viviana A Bozon; Cecile A Bulanhagui; Elisabeth Seja; Arturo Villanueva; Bradley R Straatsma; Antonio Gualberto; James S Economou; John A Glaspy; Jesus Gomez-Navarro; Antoni Ribas
Journal:  J Transl Med       Date:  2008-05-01       Impact factor: 5.531

View more
  31 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 2.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

Review 3.  Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Authors:  Jessica M Moskovitz; Jennifer Moy; Tanguy Y Seiwert; Robert L Ferris
Journal:  Oncologist       Date:  2017-05-15

Review 4.  Immunoregulatory pathways following strong inflammatory processes markedly impair CD4+ T cell responses.

Authors:  Christine M Minnar; William J Murphy
Journal:  Hum Vaccin Immunother       Date:  2016-07-13       Impact factor: 3.452

Review 5.  Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Authors:  Jason R Baird; Arta M Monjazeb; Omid Shah; Heather McGee; William J Murphy; Marka R Crittenden; Michael J Gough
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-19       Impact factor: 7.038

6.  Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Authors:  Crystal Morales Del Valle; Joseph R Maxwell; Maria M Xu; Antoine Menoret; Payal Mittal; Naomi Tsurutani; Adam J Adler; Anthony T Vella
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

7.  Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models.

Authors:  Adrienne Rothschilds; Alice Tzeng; Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine; K Dane Wittrup
Journal:  Oncoimmunology       Date:  2019-02-19       Impact factor: 8.110

Review 8.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

9.  Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity.

Authors:  Alejandro F Alice; Gwen Kramer; Shelly Bambina; Jason R Baird; Keith S Bahjat; Michael J Gough; Marka R Crittenden
Journal:  J Immunol       Date:  2017-11-17       Impact factor: 5.422

10.  Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Authors:  Alice Tzeng; Monique J Kauke; Eric F Zhu; Kelly D Moynihan; Cary F Opel; Nicole J Yang; Naveen Mehta; Ryan L Kelly; Gregory L Szeto; Willem W Overwijk; Darrell J Irvine; K Dane Wittrup
Journal:  Cell Rep       Date:  2016-12-06       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.